INTRODUCTION
■ Gene therapy for hemophilia B aims to provide long-term Factor IX (FIX) production from a single intravenous (i.v.) administration, thereby reducing disease severity from severe or moderately severe to mild or non-hemophilic.
■ AMT-061 is an investigational treatment that delivers the highly active Padua variant of FIX to the liver using an adeno-associated virus (AAV) serotype 5 vector (Figure 1 ).
■ AMT-061 is a modified version of AMT-060, which encodes the wildtype FIX protein and was studied in 10 patients in Phase 1/2.
■ A Phase 2b dose-confirmatory study of AMT-061 (NCT03489291) is ongoing. ■ Reduced annualized FIX consumption by 79%. 2, 3 ■ Reduced the frequency of total+spontaneous bleeds. 2, 3 ■ Was well tolerated, no severe treatment-related adverse events (AE) and no FIX-inhibitor development. 
HOPE-B CLINICAL TRIAL OBJECTIVE
■ To determine the endogenous FIX activity, bleeding rate, and safety profile of AMT-061 in patients with severe or moderately severe hemophilia B.
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METHODS
■ Open label Phase 3 study investigating the safety and efficacy of a one-time administration of a single dose of AMT-061 in adult patients with severe or moderately severe hemophilia B ( Table 1 ).
Subject eligibility ■ Eligibility assessed at screening (medical history, vital signs, physical examination, and blood sampling).
■ Subjects will undergo a washout (no prophylaxis for 3-10 days) for baseline FIX measurement, then resume regular prophylaxis for the lead-in.
■ Prospective lead-in phase (≥26 weeks): e-diary recording of prophylactic FIX replacement and bleeding episodes. ■ Study data will be used to seek regulatory approval of AMT-061 for adults with hemophilia B.
For more information, please visit www.ClinicalTrials.gov NCT03569891 or contact uniQure at uniQureHOPE-B@uniqure.com.
